An Update on Inhibitors of Human 14 kDa Type II s PLA2 in Development

Author: Springer, D.M.

Source: Current Pharmaceutical Design, Volume 7, Number 3, 1 February 2001 , pp. 181-198(18)

Publisher: Bentham Science Publishers

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

Recent progress in the development of inhibitors of human Type II s PLA2 as potential anti inflammatory agents is presented. While many companies have curtailed their efforts in the PLA2 area, Eli Lilly and Shionogi are continuing to advance LY 315920 (S 5920) as a potential treatment for sepsis and other diseases that have an inflammatory component. The Lilly developmental effort leading to LY 315920 is extensively reviewed, as well as the current status of other small molecular weight inhibitors of Type II s PLA2 that have been reported to be in late stage development.

Keywords: Phospholipases A2; Arachidonic acid; Lipoxygenase enzymes; anti inflammatory responses; Phosphatidylcholine micelle; Transgenic mice; Indoxam blocked; carrageenan induced; Phthalic anhydride; Analysis and Speculatin

Document Type: Review article

DOI: 10.2174/1381612013398275

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$55.10 plus tax Refund Policy